{"organizations": [], "uuid": "e95043ee0a99fbc69148231ec53d1291e03e1bc2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-carmat-says-to-keep-patient-enroll/brief-carmat-says-to-keep-patient-enrollment-pace-in-line-with-its-goal-to-finalize-pivotal-study-by-year-end-idUSFWN1QA10U", "country": "US", "domain_rank": 408, "title": "BRIEF-Carmat Says To Keep Patient Enrollment Pace In Line With Its Goal To Finalize Pivotal Study By Year-End", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.98, "site_type": "news", "published": "2018-02-21T01:23:00.000+02:00", "replies_count": 0, "uuid": "e95043ee0a99fbc69148231ec53d1291e03e1bc2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-carmat-says-to-keep-patient-enroll/brief-carmat-says-to-keep-patient-enrollment-pace-in-line-with-its-goal-to-finalize-pivotal-study-by-year-end-idUSFWN1QA10U", "ord_in_thread": 0, "title": "BRIEF-Carmat Says To Keep Patient Enrollment Pace In Line With Its Goal To Finalize Pivotal Study By Year-End", "locations": [], "entities": {"persons": [], "locations": [{"name": "copenhagen", "sentiment": "none"}, {"name": "denmark", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Carmat:\n* SAYS ADVANCES THE INTERNATIONALIZATION OF THE PIVOTAL STUDY AND OBTAINS THE APPROVAL TO PERFORM IMPLANTS IN DENMARK‍​\n* HEART CENTER OF THE RIGSHOSPITALET HOSPITAL IN COPENHAGEN SAYS TO EVALUATE THE CARMAT ARTIFICIAL HEART FOR THE TREATMENT OF END-STAGE HEART-FAILURE PATIENTS\n* SAYS EXPECT TO PURSUE STRATEGY OF CREATING A POOL OF HIGHLY SPECIALIZED CENTERS, TO INCLUDE THREE MORE CENTERS IN THE UPCOMING MONTHS\n* SAYS THIS SHOULD ALLOW TO SUSTAIN THE PATIENT ENROLLMENT PACE IN LINE WITH ITS OBJECTIVE OF FINALIZING THE PIVOTAL STUDY BY THE END OF THIS YEAR Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-21T01:23:00.000+02:00", "crawled": "2018-02-21T21:08:16.085+02:00", "highlightTitle": ""}